Marker Therapeutics, Inc.

Monthly Archives: February 2018

Are Cancer Vaccines the Future of Treatment?

TapImmune, an immuno-oncology company in Florida is currently clinically testing a vaccine specifically for triple-negative breast and ovarian cancer.
Read More

Off-the-Shelf Vaccine Investigated in Phase II Study of TNBC for Recurrence Prevention

A novel therapeutic vaccine, TPIV200, is being investigated in a new randomized, multicenter, double-blinded, placebo-controlled phase II clinical trial in patients with triple-negative breast cancer (TNBC).
Read More

TapImmune to Participate in Two Upcoming Investor Conferences

TapImmune President & CEO, Peter Hoang, will be participating in two conferences in the upcoming weeks.
Read More